[Pharmacodynamics of the new beta blockader corgard (nadolol) in patients with stress-induced angina pectoris].
Antianginal effect of a new beta-blocker corgard (nadolol) was studied in 17 male patients with stable stress angina, aged 42 to 56, in comparison to obsidan and placebo. An original method was used to assess the extent and duration of antianginal effect consisting in repeat identical treadmill exercise coupled with continuous ECG monitoring. Corgard was shown to produce a marked antianginal effect as reflected in significantly reduced ST depression and elevation of angina of effort for more than 24 hours after a single 80 mg dose. Compared to an adequate dose of propranolol, corgard is 20-25% more effective in terms of markedness, and at least 14 hours more effective in terms of duration of the effect.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000787:Angina Pectoris / Q000188:drug therapy* / Q000209:etiology; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D009248:Nadolol; D005082:Physical Exertion; D010919:Placebos; D011412:Propanolamines / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D010919:Placebos; D011412:Propanolamines; D009248:Nadolol; D011433:Propranolol
Farmakodinamika novogo beta-blokatora korgarda (nadolola) u bol'nykh so stenokardieĭ napriazheniia.